Navigation Links
Aureus Pharma Releases New Unified Knowledge Database

AurSCOPE(R) Global Pharmacology Space and Drug Target Knowledge Databases

Related to Nuclear Receptors and Proteases

PARIS, August 18 /PRNewswire/ -- Aureus Pharma, a leading provider of knowledge management solutions that accelerate life sciences discovery, announced today the release of three new AurSCOPE(R) Target knowledge databases. The new offerings include knowledge databases for the important drug targets Nuclear Receptor and Protease, as well as the centralized product AurSCOPE(R) Global Pharmacology Space (AurSCOPE(R) GPS). AurSCOPE GPS comprises all of the pharmaceutically important therapeutic targets including G-Protein coupled receptors (GPCR), kinases, ion channels, nuclear receptors and proteases.

Nuclear receptor proteins are integral to critical metabolic processes and implicated in diseases including diabetes, cancer, and heart disease. Likewise, proteases are a major focus for therapeutic intervention being linked to viral diseases including HIV, inflammation and neurogenerative disorders.

AurSCOPE GPS and other AurSCOPE Knowledge databases streamline discovery efforts with thorough assessment of selectivity and off-target effects at the earliest stages of the drug discovery pipeline.

"The release of AurSCOPE Global Pharmacology Space (GPS), Nuclear Receptor and Protease represents an exciting milestone for Aureus Pharma. These powerful new products considerably extend Aureus' knowledge management solution by providing our pharmaceutical customers unique access to the druggable therapeutic target space." said Jason Theodosiou, President and CEO of Aureus Pharma. "Using AurSCOPE Knowledge databases, researchers easily employ knowledge-driven hypotheses to drive better informed decisions during drug discovery."

Aureus experts will demonstrate AurSCOPE GPS, AurSCOPE Nuclear Receptor and AurSCOPE Protease products at the American Chemical Society (ACS) meeting in Philadelphia, PA August 18th -21st.

About Aureus Pharma

Aureus Pharma headquartered in Paris, France is a privately held

knowledge management based solutions provider for the life sciences

industry. Aureus Pharma accelerates new drug discovery by providing

knowledge databases which contain high quality quantitative information

for both chemistry and biology. Researchers gain rapid access to

knowledge for important drug target classes as well as ADME/Tox topics.

The information contained in the Aureus Pharma system is of primary

importance to aid in lead discovery and optimization as well as to

build predictive models. For further information on how Aureus Pharma

helps researchers turn data into discovery visit

Media Contact

Mary E. Donlan, Ph.D.

Director of Marketing

Aureus Pharma

Phone:+33-1-40-18-57-59 / +33-6-76-19-51-77

SOURCE Aureus Pharma
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Aureus Pharma Releases AurPROFILER(R) - a New and Powerful Pharmacology Profiling Solution
2. Aureus Pharma Announces Date of 2008 Annual User Symposium
3. QSB Anti-Virulence Platform Inhibits Biofilm Formation by Staphylococcus Aureus MRSA and Candida sp
4. Aureus Pharma Announces Renewal and Expansion of Licensing Agreement With Bristol-Myers Squibb for its AurSCOPE Knowledge Databases
5. New ActivePure Technology Proven To Reduce Exposure to Methicillin Resistant Staphylococcus Aureus (MRSA)
6. Lotus Pharmaceuticals Announces Second Quarter 2008 Results
7. XTL Biopharmaceuticals Receives Notice of Non-Compliance with Nasdaq Marketplace Rule Due to Changes in Board Composition
8. Catalyst Pharmaceutical Partners Reports Second Quarter 2008 Financial Results
9. ARCA biopharma Appoints William R. Hiatt as Director of Clinical and Regulatory Strategy
10. Huifeng Bio-Pharmaceutical (HFGB) Reports over $5 Million in Gross Sales; Record Results for the First Half of 2008
11. Ondine Biopharma Announces Second Quarter 2008 Financial Results
Post Your Comments:
(Date:11/25/2015)... , November 25, 2015 ... Report is a professional and in-depth study on ...      (Logo: ) , ... the industry including definitions, classifications, applications and industry ... for the international markets including development trends, competitive ...
(Date:11/24/2015)... , Nov. 24, 2015 Halozyme Therapeutics, Inc. (NASDAQ: ... in New York on Wednesday, December 2 ... Torley , president and CEO, will provide a corporate overview. ... York at 1:00 p.m. ET/10:00 a.m. PT . ... relations, will provide a corporate overview. --> th ...
(Date:11/24/2015)... -- Clintrax Global, Inc., a worldwide provider of clinical research services headquartered ... the company has set a new quarterly earnings record in Q3 ... posted for Q3 of 2014 to Q3 of 2015.   ... , with the establishment of an Asia-Pacific ... United Kingdom and Mexico , with ...
(Date:11/24/2015)... 2015 --> ... released by Transparency Market Research, the global non-invasive prenatal ... of 17.5% during the period between 2014 and 2022. ... Industry Analysis, Size, Volume, Share, Growth, Trends and Forecast ... market to reach a valuation of US$2.38 bn by ...
Breaking Biology Technology:
(Date:11/9/2015)... 2015 ... "Global Law Enforcement Biometrics Market 2015-2019" ... ) has announced the addition ... Market 2015-2019" report to their offering. ... ) has announced the addition of ...
(Date:11/2/2015)... Calif. , Nov. 2, 2015  SRI International ... million to provide preclinical development services to the National ... contract, SRI will provide scientific expertise, modern testing and ... variety of preclinical pharmacology and toxicology studies to evaluate ... --> The PREVENT Cancer Drug Development Program ...
(Date:10/29/2015)... 2015 Daon, a global leader in mobile ... a new version of its IdentityX Platform , ... America have already installed IdentityX v4.0 and ... FIDO UAF certified server component as an ... FIDO features. These customers include some of the largest ...
Breaking Biology News(10 mins):